Juanmonino/iStock Unreleased via Getty Images GSK ( NYSE: GSK ) said it has started to appeal a recent court ruling in Delaware that allowed tens of thousands of lawsuits to go forward as part of an ongoing litigation related to claims that its discontinued heartburn drug, Zantac, caused cancer. The British drugmaker said late Monday that it filed an application for appeal after Delaware Superior Court Judge Vivian Medinilla ruled in favor of more than 70,000 Zantac-related lawsuits in May. Other defendants, Pfizer ( NYSE: PFE ), Sanofi ( NASDAQ: SNY ), and Boehringer Ingelheim, have also joined with GSK ( GSK ) in filing for the appeal, which, if granted, will go to the Delaware Supreme Court for review.
If the Delaware Superior Court denies it, the companies intend to appeal directly to the Supreme Court, a decision from which is expected sometime later this year, GSK ( GSK ) said. Concurrently, GSK said a woman called Eugenia Kasza, who alleged that Zantac use caused her breast cancer, has decided to drop her case. She sought voluntary dismissal of her case days before a trial on the litigation was set to start.
“GSK did not settle Ms. Kasza’s claim and has not paid anything in exchange for the voluntary dismissal,” the company said. More on GSK GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK plc (GSK) Q1 2024 Earnings Call Transcript GSK, SpringWorks end collaboration agreement GSK wins FDA nod to expand label for RSV vac.
